What role does Natac Natural play ingredients in the market for natural ingredients and what expectations of growth and investment in the health sector?
Natac Natural Ingredients plays a key role as a supplier of high quality natural ingredients with health benefits. We investigate, develop, manufacture and market healthy ingredients of natural origin, mainly Omega-3 plants and oil extracts coming from fishwhich are destined to industries such as nutraceutical, food or pharmaceutical. Today, there is a clear trend in the market towards the natural and towards the prevention of the disease. We are dedicated to manufacturing and selling everything related to those natural ingredients. He global natural ingredient market grows between 7% and 10% per yearbut we have overcome those figures with growth of 30% in recent years. Therefore, this is a sector that presents numerous investment opportunities.
Could you share the main income, EBITDA and net benefit data of the latest years?
In the last four or five years, our annual growth rate has been above 30%. We have stopped 20.35 million in 2021, to touch the 36 million euros in 2024which represents a historical sales record and an increase of 35% with respect to the exercise of 2023. At the standardized Ebitda level, last year was 13.82 million, being the 2023 9.41 million.
What are the innovations implemented in the development of products that contribute to improving health and prolonging life?
Since our beginnings, we have always inverted in innovation, both product and technology, To develop the best natural ingredients and thus respond to the market and our customers. We have developed a deep knowledge of methods of extraction, fractionation and purification of plant bioactive compounds. For example, we have intensified the Research in molecules such as polyphenols and triterpenoides, as well as in omega-3which has a fundamental role in the prevention of chronic diseases or the improvement of cognitive function. We also work on the extraction and purification of biomolecules present in plants to serve as a starting point for the development of drugs for rare diseases.
By product line, how much does each one weigh in the global results of the group?
By business segments, most of our income came from Pharmaceutical market (+42%) and nutraceutical (41.84%). The rest, of ingredients for the animal, food nutrition and omega 3 industry.
What is the current level of indebtedness of the group?
The debt of Nation stood in 56.75 million last year, 7.36 million more than in 2023due to the investments made in our Omega-3 plant and the expansion work in the Hervás factory within the Sustainext project. Even so, the ratio DFN/EBITDA presents an improvement with respect to the previous exercise having passed from the 5,25 al 4,11.
What research and innovation strategies are being promoted in Natac Natural Ingredients to adapt ingredients with anti -inflammatory and antioxidant properties to the demand for current products?
There is a great tendency and need for natural ingredients with functional anti -inflammatory and antioxidant abilities, both in human and animal food. What we do is review all scientific literature and, with our abilitieswe put in the market industrial and commercially viable products that meet existing regulations and that have these beneficial properties. This highlights our work with the active ingredients of the olive tree, our most emblematic plant and in which we have been working on these factors, through polyphenols and triterpenes, allowing the market to reach the market whose activity was scientifically known but that no one had been able to place within reach of the consumer in a consistent way and an affordable price.
Where are the next growth routes?
We want to increase ours market share in the different industries in which we operate and expand our presence in high performance markets such as United Kingdom, Latin America and the Middle East. Our growth strategy will be based on increasing the rate of use of Hervás’s productive capacity, in the sale of Omega 3 and the production of APIs (Active Pharmaceutical Ingredients). Another growth lever will be the launch of new products. A priori we do not contemplate growing in an inorganic way but if an opportunity arises we would study it.
What challenges face health sector companies in terms of regulations and technology integration?
He Challenge is standardizing something that is in natureand that, therefore, it is totally variable, in such a way that it always has the same effect. To do this, we have led to technical excellence as old as the use of plants for disease prevention. In order to guarantee the quality, safety, authenticity and traceability of our ingredients, we manufacture in accordance with the most prestigious quality standards and certifications for each market. In addition, we have developed an innovative risk analysis system of raw materials known as HABOID. Another great challenge is the difference in the regulation of plants between countries. While in some they are considered medications, in others they are classified as food. This requires us to implement both food and pharmaceutical regulations in our production plant, and have a deep and updated knowledge of the legislation in each of the More than 40 countries where we operate.
What forecasts have the demand for health products related to health?
The demand for natural products will continue to increase in an increasingly aware society about the importance of preventive health care. The tendency towards a healthier lifestyle along with the desire to consume natural products favors the growth of our industry. In addition, the aging of the world population will boost the demand for this type of alternatives, which help disease prevention and health maintenance throughout life. In general, we are very optimistic about the future of natural ingredients in health and well -being.